GSK Acquires CMG1A46 From Chimagen Biosciences For $300M To Boost Immunology Pipeline, Targeting B Cell-Driven Autoimmune Diseases Like Lupus; Chimagen Eligible For Additional $550M In Milestone Payments
GSK Acquires CMG1A46 From Chimagen Biosciences For $300M To Boost Immunology Pipeline, Targeting B Cell-Driven Autoimmune Diseases Like Lupus; Chimagen Eligible For Additional $550M In Milestone Payments
GSk以30000萬美元從Chimagen生命科學公司收購CMG1A46，以增強免疫學管道，針對像狼瘡這樣由b細胞驅動的自身免疫性疾病；Chimagen有資格獲得額外的55000萬美元的里程碑支付
GSK Acquires CMG1A46 From Chimagen Biosciences For $300M To Boost Immunology Pipeline, Targeting B Cell-Driven Autoimmune Diseases Like Lupus; Chimagen Eligible For Additional $550M In Milestone Payments
GSk以30000萬美元從Chimagen生命科學公司收購CMG1A46，以增強免疫學管道，針對像狼瘡這樣由b細胞驅動的自身免疫性疾病；Chimagen有資格獲得額外的55000萬美元的里程碑支付
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間